Ashland Wraps Up Expansion of Pharmaceutical Plant in Brazil
ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.
Ashland Wraps Up Divestment of Avoca Business to Mane
ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.
Ashland Presents Attractive Upside Emerging From The Downcycle
Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector.
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.
Ashland's Earnings Outpace Estimates, Revenues Miss in Q1
Organic sales volume growth in ASH's Personal Care, Specialty Additives and Intermediates segments largely offset lower volumes in Life Sciences in Q1.
Ashland Inc. (ASH) Q1 2025 Earnings Call Transcript
Ashland Inc. (NYSE:ASH ) Q1 2025 Earnings Conference Call January 29, 2025 9:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo Chris Parkinson - Wolfe Research John Roberts - Mizuho David Begleiter - Deutsche Bank Jeff Zekauskas - JPMorgan Mike Harrison - Seaport Research Partners Bhavesh Lodaya - BMO Capital Markets Josh Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2025 Earnings Conference Call.
Here's What Key Metrics Tell Us About Ashland (ASH) Q1 Earnings
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ashland (ASH) Surpasses Q1 Earnings Estimates
Ashland (ASH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.45 per share a year ago.
Stay Ahead of the Game With Ashland (ASH) Q1 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Ashland (ASH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Forget The S&P 500 - 3 Small Dividend Stocks At Big Discounts
President Trump inherits a historically expensive stock market, with the Shiller P/E ratio indicating potentially subdued long-term returns for the S&P 500. Despite high valuations, opportunities exist, especially in smaller and mid-cap stocks, which are undervalued compared to large-cap stocks. The market's top-heavy nature, driven by FANG+ stocks, presents a risk/reward shift, making smaller companies more attractive.
Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for
Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bear of the Day: Ashland Inc (ASH)
This stock does not have the best looking chart and has seen estimates continue to fall.
